US FDA’s Most Controversial Drug Approval Decisions, From A To Z
Executive Summary
With action imminent on Biogen’s Alzheimer’s drug aducanumab, the Pink Sheet looks back at 10 of FDA’s most controversial drug approval decisions, from Addyi to Zohydro.